International journal of obesity (2005) · 2026
Utilization and outcomes of nutrient-stimulated hormone therapies in patients undergoing bariatric surgery.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Villatoro Santos Claudia R, Estrada Tock Hector D, Tang Haoran, McEwen Laura N, Kraftson Andrew, Herman William H, Rothberg Amy E
Аннотация
OBJECTIVE: To describe the impact of nutrient-stimulated hormone (NuSH) therapies on weight loss by bariatric surgery type, diabetes status, and timing of initial NuSH prescription.
METHODS: Retrospective study of 1638 adults who underwent bariatric surgery at a single academic medical center between 2015 and 2022. Baseline demographics, NuSH therapy prescriptions, and follow-up weights were obtained from electronic health records. We calculated percent total weight loss (%TWL) over time using linear mixed models.
RESULTS: Patients who underwent Roux-en-Y gastric bypass (RYGB) had greater %TWL compared to those who underwent sleeve gastrectomy (SG). Those without diabetes had greater %TWL compared to those with diabetes. At 72 months, adjusted average %TWL was highest in patients who received NuSH prescriptions both before and after surgery (22.7%, 95% CI: 17.9-27.5), followed by those with prescriptions only after surgery (19.9%, 95% CI: 18.3-21.4) and those without prescriptions (19.6%, 95% CI: 18.1-21.2). The greatest %TWL was seen in patients who had prescriptions within 6 months after surgery.
CONCLUSION: Individuals who underwent RYGB and who did not have diabetes had the highest %TWL. Receiving a NuSH prescription both before and after surgery and early NuSH initiation were associated with the greatest %TWL.
METHODS: Retrospective study of 1638 adults who underwent bariatric surgery at a single academic medical center between 2015 and 2022. Baseline demographics, NuSH therapy prescriptions, and follow-up weights were obtained from electronic health records. We calculated percent total weight loss (%TWL) over time using linear mixed models.
RESULTS: Patients who underwent Roux-en-Y gastric bypass (RYGB) had greater %TWL compared to those who underwent sleeve gastrectomy (SG). Those without diabetes had greater %TWL compared to those with diabetes. At 72 months, adjusted average %TWL was highest in patients who received NuSH prescriptions both before and after surgery (22.7%, 95% CI: 17.9-27.5), followed by those with prescriptions only after surgery (19.9%, 95% CI: 18.3-21.4) and those without prescriptions (19.6%, 95% CI: 18.1-21.2). The greatest %TWL was seen in patients who had prescriptions within 6 months after surgery.
CONCLUSION: Individuals who underwent RYGB and who did not have diabetes had the highest %TWL. Receiving a NuSH prescription both before and after surgery and early NuSH initiation were associated with the greatest %TWL.